Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

PUBLICATION DATE

15 results
Display

Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial

Yhim HY, Choi WI, Kim SH, Nam SH, Kim KH, Mun YC, Oh D, Hwang HG, Lee KW, Song EK, Kwon YS, Bang SM

BACKGROUND/AIMS: Limited data are available regarding the efficacy of rivaroxaban for the treatment of cancer-associated venous thromboembolism (VTE). The aim of this study was to evaluate the effectiveness and safety...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer

Lee JH, Oh YM, Lee SD, Lee JS

BACKGROUND: Low-molecular-weight heparin (LMWH) is the standard treatment for venous thromboembolism (VTE) in patients with active cancer. However, use of factor Xa inhibitors, such as rivaroxaban, is increasing on the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation

Kim H, Kim H, Cho SK, Kim JB, Joung B, Kim C

BACKGROUND AND OBJECTIVES: Rivaroxaban is noninferior to warfarin for preventing stroke or systemic embolism in patients with high-risk atrial fibrillation (AF) and is associated with a lower rate of intracranial...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Study on the Efficacy and Safety of Rivaroxaban in Urologic Cancer-Associated Venous Thromboembolism

Lee JH, You D, Lee SD, Oh YM, Lee JS

PURPOSE: Although direct oral anticoagulants (DOACs) are recommended as an alternative to low-molecular weighted heparin for cancer-associated venous thromboembolism (VTE), there is no firm evidence on the efficacy and safety...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Epidural hematoma after total knee arthroplasty in a patient receiving rivaroxaban: A case report

Shin S, Kang H, Lee JW, Kim HG, Choi ES

Rivaroxaban, a factor Xa inhibitor, is one of the newly developed direct oral anticoagulants (DOAC). In recent times, it has been increasingly used in the prevention of pulmonary embolism in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Real World Comparison of Rivaroxaban and Warfarin in Korean Patients with Atrial Fibrillation: Propensity Matching Cohort Analysis

Jeong HK, Lee KH, Park HW, Yoon NS, Kim MC, Lee N, Kim JS, Ahn Y, Jeong MH, Park JC, Cho JG

Rivaroxaban has emerged as a potential alternative to warfarin for the prevention of thromboembolism in patients with atrial fibrillation (AF). However, there has been concern for the risk of major...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Rivaroxaban and Acetylsalicylic Acid for Prevention of Venous Thromboembolism Following Total Knee Arthroplasty in Korean Patients

Chung KS, Shin TY, Park SH, Kim H, Choi CH

PURPOSE: To investigate the incidence of venous thromboembolism (VTE) after total knee arthroplasty (TKA) with chemoprophylaxis using acetylsalicylic acid (AA) or rivaroxaban in Korean patients. MATERIALS AND METHODS: Between May 2011...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Incidence and characteristics of major bleeding among rivaroxaban users with renal disease and nonvalvular atrial fibrillation

Patel MR, Peacock WF, Tamayo S, Sicignano , Hopf KP, Yuan Z

OBJECTIVE: Patients with nonvalvular atrial fibrillation (AF) and renal disease (RD) who receive anticoagulation therapy appear to be at greater risk of major bleeding (MB) than AF patients without RD....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Acute Spinal Subdural Hematoma in a Patient Taking Rivaroxaban

Bang WS, Kim KT, Park MK, Sung JK, Lee H, Cho DC

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Intravenous Thrombolysis in Patients with Stroke Taking Rivaroxaban Using Drug Specific Plasma Levels: Experience with a Standard Operation Procedure in Clinical Practice

Seiffge DJ, Traenka C, Polymeris , Thilemann , Wagner B, Hert L, Müller MD, Gensicke H, Peters N, Nickel CH, Stippich C, Sutter R, Marsch S, Fisch U, Guzman R, De Marchis GM, Lyrer PA, Bonati LH, Tsakiris D, Engelter S

BACKGROUND AND PURPOSE: Standard operating procedures (SOP) incorporating plasma levels of rivaroxaban might be helpful in selecting patients with acute ischemic stroke taking rivaroxaban suitable for IVthrombolysis (IVT) or endovascular...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Hemorrhagic pericarditis associated with rivaroxaban in an atrial fibrillation patient with pacemaker

Rhew SH, Kim SS

Rivaroxaban is a new oral anticoagulant used for the prevention of stroke in patients with atrial fibrillation. Hemorrhagic pericarditis is known to occur with rivaroxaban; however, only a few case...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Rivaroxaban for Thromboprophylaxis in Patients with Antiphospholipid Syndrome

Park JH, Song JS, Choi ST

The main treatment for Antiphospholipid syndrome (APS) is long-term anticoagulation with an oral vitamin K antagonist, although these are associated with numerous problems. Rivaroxaban is a direct anti-factor Xa inhibitor,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Multiple Intracranial Hemorrhage Following Intravenous Recombinant Plasminogen Activator in the Patients Taking Rivaroxaban

Ryu JC, Kwon JH, Choi SH, Kim WJ

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Practice Preferences on Dabigatran and Rivaroxaban for Stroke Prevention in Patients with Non-valvular Atrial Fibrillation

Park YK, Kang JE, Kim SJ, La HO, Rhie SJ

OBJECTIVE: Prescription rate of dabigatran and rivaroxaban, which are the direct oral anticoagulants (DOAC), has increased. We have analyzed the prescription trend and medication use of dabigatran and rivaroxaban in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparisons of Bleeding Risks between Rivaroxaban and Dalteparin for Treatment of Venous Thromboembolism in Cancer Patients

Kim YK, An SH, Kim JY, Chung JE, Gwak HS

BACKGROUND: Venous thromboembolism (VTE) is a common and life-threating condition in cancer patients. Low molecular weight heparins (LMWH), such as dalteparin, are recommended in the treatment of VTE. Also, rivaroxaban,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr